Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology | GenomeWeb

Originally published May 10.

By Turna Ray

Continuing efforts to diversify its product pipeline, Myriad Genetics announced this week that it has acquired an exclusive license to commercialize Chronix Biomedical's technology for the early detection of cancer.

Chronix has yet to complete validation studies for its prostate, breast, and colon cancer tests, however, so questions remain as to when the license will begin adding to Myriad's revenues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.